ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Phocas Financial Corp.

Phocas Financial Corp. decreased its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 5.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 60,215 shares of the biopharmaceutical company’s stock after selling 3,782 shares during the quarter. Phocas Financial Corp.’s holdings in ACADIA Pharmaceuticals were worth $926,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Quest Partners LLC boosted its position in ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 1,047 shares during the period. Natixis Advisors LLC raised its stake in shares of ACADIA Pharmaceuticals by 58.6% in the third quarter. Natixis Advisors LLC now owns 40,488 shares of the biopharmaceutical company’s stock valued at $623,000 after acquiring an additional 14,961 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in ACADIA Pharmaceuticals by 26.6% in the third quarter. Oppenheimer Asset Management Inc. now owns 37,429 shares of the biopharmaceutical company’s stock valued at $576,000 after purchasing an additional 7,872 shares during the period. Victory Capital Management Inc. grew its stake in ACADIA Pharmaceuticals by 2.9% during the 3rd quarter. Victory Capital Management Inc. now owns 97,130 shares of the biopharmaceutical company’s stock worth $1,494,000 after purchasing an additional 2,708 shares in the last quarter. Finally, Atria Investments Inc increased its holdings in ACADIA Pharmaceuticals by 10.8% during the 3rd quarter. Atria Investments Inc now owns 24,437 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 2,384 shares during the period. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on ACAD shares. Raymond James reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 10th. Royal Bank of Canada reduced their price objective on shares of ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Citigroup lowered their target price on shares of ACADIA Pharmaceuticals from $30.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. UBS Group cut their price target on ACADIA Pharmaceuticals from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $25.56.

Insider Buying and Selling

In other news, insider James Kihara sold 4,073 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $68,467.13. Following the completion of the sale, the insider now directly owns 19,863 shares of the company’s stock, valued at $333,897.03. This trade represents a 17.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Brendan Teehan sold 10,329 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total value of $173,630.49. Following the completion of the sale, the chief operating officer now owns 62,105 shares in the company, valued at approximately $1,043,985.05. This trade represents a 14.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,661 shares of company stock valued at $414,551 over the last three months. 28.30% of the stock is currently owned by company insiders.

ACADIA Pharmaceuticals Stock Performance

NASDAQ ACAD opened at $16.21 on Wednesday. ACADIA Pharmaceuticals Inc. has a one year low of $14.15 and a one year high of $32.59. The firm has a market cap of $2.70 billion, a PE ratio of 20.78 and a beta of 0.38. The firm’s fifty day moving average is $15.60 and its two-hundred day moving average is $15.99.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.14 by $0.06. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The firm had revenue of $250.40 million during the quarter, compared to the consensus estimate of $248.83 million. During the same period in the prior year, the business earned ($0.40) EPS. The firm’s revenue was up 18.3% compared to the same quarter last year. Research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.72 earnings per share for the current year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.